Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years

BAGSVÆRD, Denmark, March 26, 2021 /PRNewswire/ -- Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years.1

Over the last 20 years, the global...

Read more: Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesit...

More Articles …

  1. Upstox, one of India's leading broking firms, joins IPL as an Official Partner
  2. Antengene Appoints Kevin Lynch as Chief Medical Officer
  3. The Chairman in Hong Kong Takes No.1 Spot at Asia's 50 Best Restaurants 2021 Awards
  4. SOPHiA GENETICS and Hitachi Announce Collaboration to Advance Data Driven Precision Medicine
  5. Integrated Media Technology Limited Announces Closing of $4.602 Million Registered Direct Offering of Ordinary Shares
  6. Techking Custom-made Tires Come to Full Play in Australia, Well Recognized by Rio Tinto and XCMG
  7. Saasyan Appoints Sidney Minassian As Its New CEO
  8. Unique Crystals & Stones Launches Online Store for Positive and Healing Energy During the Pandemic
  9. Really Simple Systems Releases New CRM Calendar
  10. Cboe Global Markets Agrees to Acquire Chi-X Asia Pacific, Expanding Global Footprint into Australia and Japan